Trial of Spinraza at High Dose in SMA Patients Who Used Evrysdi Planned

Trial of Spinraza at High Dose in SMA Patients Who Used Evrysdi Planned

306360

Trial of Spinraza at High Dose in SMA Patients Who Used Evrysdi Planned

[Editor’s note: An earlier version of this story did not specify in its opening statement that Spinraza’s use in this proposed trial would follow Evrysdi’s use.] Biogen plans to launch a Phase 3b trial into the safety and efficacy of a higher dose of Spinraza (nusinersen) in children, teenagers, and adults with later-onset spinal muscular atrophy (SMA) previously treated with Evrysdi (risdiplam). The trial, to be called ASCEND and to run for roughly 2.5 years, expects to…

You must be logged in to read/download the full post.